Previous 10 | Next 10 |
home / stock / anpcy / anpcy news
ANGLE plc Director/PDMR Shareholding Exercise of Options and Total Voting Rights GUILDFORD, SURREY / ACCESSWIRE / July 7, 2021 / ANGLE plc ('ANGLE' or the 'Company') (AIM:AGL) (OTCQX:ANPCY), a world-leading liquid biopsy company, announces that it has agreed to allot 1,023,826 new ordin...
Exercise of options and total voting rights GUILDFORD, UK / ACCESSWIRE / July 2, 2021 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and allotted 48,333 new Ordinary shares of £0.10 ea...
ANGLE plc ('the Company') Result of 2021 Annual General Meeting GUILDFORD, SURREY / ACCESSWIRE / June 30, 2021 / ANGLE plc (AIM:AGL) (OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were...
GUILDFORD, SURREY / ACCESSWIRE / June 18, 2021 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, confirms that its Annual General Meeting (AGM) will be held as a closed meeting at 2:00 pm on Wednesday 30 June 2021 at ANGLE plc, 10 Nugent Road, Surrey Research Park, ...
DIFFERENCES FOUND IN EGFR MUTATIONS BETWEEN ctDNA AND CTCs IN MATCHED LIQUID BIOPSIES FROM NON-SMALL LUNG CANCER PATIENTS Study supports analysis of CTCs, together with ctDNA, from serial liquid biopsies to provide information on disease progression and drug resistance CTCs foun...
UPDATE ON SUBMISSION FOR FDA CLEARANCE OF THE PARSORTIX SYSTEM Response to Additional Information Request made to FDA as planned GUILDFORD, UK / ACCESSWIRE / June 4, 2021 / ANGLE plc (OTCQX:ANPCY)(AIM:AGL), a world-leading liquid biopsy company, confirms that it has completed the w...
BREAKTHROUGH RESEARCH SUPPORTS POTENTIAL USE OF PARSORTIX IN PREVENTION OF RELAPSE OF BREAST CANCER PATIENTS IN REMISSION Parsortix system successfully used to harvest cancer cells "hibernating" in the bone marrow of breast cancer patients Parsortix enrichment of these cancer cells...
Parsortix system consistently harvests CTCs of high quality Research paves the way for downstream molecular analysis to enable targeted treatment in this hard-to-treat cancer GUILDFORD, UK / ACCESSWIRE / May 20, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biop...
GUILDFORD, SURREY / ACCESSWIRE / May 19, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and allotted 216,000 new Ordinary shares of £0.10 each ("New Ordinary Shares") in the Company...
Parsortix system harvests intact CTCs for whole genomic sequencing identifying multiple druggable targets Study demonstrates ctDNA and CTCs can both be analysed using the same blood sample GUILDFORD, UK / ACCESSWIRE / May 11, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leadi...
News, Short Squeeze, Breakout and More Instantly...
Angle Plc Surrey ADR Company Name:
ANPCY Stock Symbol:
OTCMKTS Market:
Angle Plc Surrey ADR Website:
GUILDFORD, SURREY / ACCESSWIRE / July 11, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed. For further information: Notes for editors About ANG...
GUILDFORD, SURREY / ACCESSWIRE / June 18, 2024 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that the audited Annual Report a...
PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT THE 2024 ANNUAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH ANGLE presenting two posters highlighting the utility of CTC & ctDNA dual analysis and ANGLE's DNA Damage Response assay GUILDFORD, SURREY / ACCESSWIRE / June 11, ...